Meeting
2024 ASCO Annual Meeting
Safety and preliminary efficacy of EIK1001 in combination with atezolizumab in participants with advanced solid tumors.
Authors
Manish R. Patel
Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL
Manish R. Patel , Drew W. Rasco , Melissa Lynne Johnson , Omid Hamid , David Sommerhalder , Carolyn Cho , Meihua Wang , Etah Kurland
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Clinical Trial Registration Number
NCT04196530
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2618)
DOI
10.1200/JCO.2024.42.16_suppl.2618
Abstract #
2618
Poster Bd #
97
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang
Poster
2021 ASCO Annual Meeting
Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer.
First Author: Francisco Robert
First Author: Alison M. Schram
Poster
2021 ASCO Annual Meeting
Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.
First Author: Ecaterina Elena Dumbrava